Blog

Vincent Rajkumar: Key recommendations for CART and bispecifics for relapsed myeloma

Vincent Rajkumar/X

Oct 27, 2024, 11:46

Vincent Rajkumar: Key recommendations for CART and bispecifics for relapsed myeloma

“Key recommendations for CART and bispecifics for relapsed myeloma presented at Myeloma Canada Scientific Roundtable by Hira Mian

Agree. Great principles.”

Rahul Banerjee shared this post on X adding:

“Very well stated!

Worth noting the emphasis on candidacy at every juncture.

For many Multiple Myeloma patients, more important than comparative efficacy of BCMA CAR-T vs TCE vs ADC (even though we all obsess over it) is their safety and logistics in terms of what makes the most sense!”

Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He also chairs the Board of directors of The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee.

His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.